{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:39Z","timestamp":1764510519218,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.bbmt.2015.06.007","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T02:35:16Z","timestamp":1434422116000},"page":"1926-1931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-0464","authenticated-orcid":false,"given":"Paolo F.","family":"Caimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basem M.","family":"William","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos H.","family":"Silva Rondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda W.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica L.","family":"Campagnaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanton L.","family":"Gerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Reese-Koc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Creger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.06.007_bib1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.06.007_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.06.007_bib3","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol\u2014a groupe d'Etude des lymphomes de l'Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.06.007_bib4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A\u00a015-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/bmt.2010.95","article-title":"Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab","volume":"46","author":"Smith","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.bbmt.2009.07.017","article-title":"Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma","volume":"15","author":"Fenske","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib7","first-page":"CD007678","article-title":"High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults","author":"Schaaf","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bbmt.2015.06.007_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2014.04.003","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis","volume":"92","author":"Rancea","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bbmt.2015.06.007_bib9","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.06.007_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clml.2013.03.009","article-title":"Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma","volume":"13","author":"William","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2015.06.007_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.06.007_bib12","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428190500527769","article-title":"Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation","volume":"47","author":"Puig","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.06.007_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00277-001-0413-8","article-title":"Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma","volume":"81","author":"Hanel","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2015.06.007_bib14","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.1992.10.11.1682","article-title":"High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma","volume":"10","author":"Lazarus","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.06.007_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbmt.2004.09.003","article-title":"High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed\/refractory lymphoma: an effective regimen with low morbidity and mortality","volume":"11","author":"Wadhwa","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","article-title":"BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2015.06.007_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.bmt.1703367","article-title":"Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?","volume":"29","author":"Wadhwa","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Statist Assoc"},{"key":"10.1016\/j.bbmt.2015.06.007_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0R Stat Soc Ser B"},{"key":"10.1016\/j.bbmt.2015.06.007_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/sim.4780120803","article-title":"Kaplan-Meier, marginal or conditional-probability curves in summarizing competing risks failure time data","volume":"12","author":"Pepe","year":"1993","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2015.06.007_bib21","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large b-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.06.007_bib22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","article-title":"High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma","volume":"34","author":"Wang","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib24","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.06.007_bib25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.06.007_bib26","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.22911","article-title":"The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation","volume":"110","author":"Filmont","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2015.06.007_bib27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1634\/theoncologist.2010-0054","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis","volume":"15","author":"Terasawa","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2015.06.007_bib28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115004097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115004097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:52:02Z","timestamp":1761058322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115004097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1083879115004097"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.06.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}